Two purported Ventyx Biosciences stockholders filed lawsuits in New York state court on Feb. 4 and Feb. 5, 2026, against the company and its board over alleged false or misleading statements and omissions in Ventyx’s proxy materials related to its pending merger with Eli Lilly. The complaints seek to block the transaction unless additional disclosures are made, along with damages and attorneys’ fees; Ventyx said the claims are without merit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ventyx Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-064082), on February 23, 2026, and is solely responsible for the information contained therein.